Mark Benedyk Email & Phone Number

Sweetwater Capital is a boutique secondaries private equity firm that helps General & Limited Partners generate liquidity and rebalance private equity exposure across multiple asset types. At Sweetwater, I provide Advisory and General Partner support on direct secondary life science transactions in areas including oncology, infectious disease, inflammation, pharmacy services, and medical devices. Also provide portfolio strategic investment support for the Texas Treasury Safekeeping Trust Company client as part of administration of its $300M Enterprise Technology Fund portfolio. Board member at Treasury Safekeeping Trust Company portfolio companies Alafair Biosciences, BioSigID and Pulmotect and board observer at Shape Memory Medical.

Alafair Biosciences is a life sciences company specializing in the development and commercialization of biomaterials and biomedical devices to enhance internal wound healing. The company develops proprietary hydrogel film products to address post-surgical complication of unwanted soft tissue adhesions that can severely impact healing and mobility in patients undergoing tendon or nerve surgery. It also develops membrane, bilayer, and injectable gel solutions for applications in scar prevention, wound care, and tissue reconstruction. The Company was founded in 2011 and is based in Austin, Texas.

Houston, Texas, Us

Pulmotect is a clinical stage biopharmaceutical company that develops immunotherapy products to reduce morbidity and mortality in patients at risk of severe respiratory infection.Pulmotect products utilize a platform technology that stimulates the body’s innate immune system to provide safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague).

Business and Corporate Development consultancy

San Diego, Us

Lewisville, Tx, Us

Biometric Signature ID is based in Dallas, Texas and is a leading developer of biometric ID verification software solutions using multi-factor authentication (MFA). Its innovative identity solution BioSig-ID authenticates individuals with a unique finger or mouse drawn password that imposters cannot replicate. Biometric Signature ID has been named to the committee developing the next generation of Identity Proving and Verification standards (IDP-V) that will be ANSI (American National Standards Institute) approved.

Madison, Wisconsin, Us

AmebaGone is developing novel biocontrols for crop bacterial infections using proprietary strains of beneficial soil amoebae to replace the 50,000 pounds of antibiotics sprayed on US crops every year to treat and prevent crop bacterial infections. AmebaGone’s first program has been vetted in two field trials and the Company has secured >$3.5M in non-dilutive funding from sources including the NIH, NSF, and USDA, and is the winner of the Life Sciences category of the 2018 Wisconsin Governor’s Business Plan Competition.

Telephus is developing TPH 101, a monoclonal antibody designed to target antibiotic-resistant staph infections (including those caused by methicillin-resistant Staphylococcus aureus, (MRSA)) in patients undergoing two-stage septic revision surgery due to infection of artificial knee implants. Clinical candidate selection is complete for our lead program, TPH 101, and lead selection for our follow-on program, TPH 201. Both target key staphylococcal enzymes critical for MRSA virulence, colonization and replication. We have a patent estate of 17 issued patents and 17 pending applications.We see a significant role for TPH 101 not only in orthopedic septic revision procedures, but also in other clinical settings such as infective endocarditis, MRSA infections in peritoneal dialysis patients and in other implantable device infections where staphylococcal infections contribute to high morbidity and mortality.Telephus holds global, exclusive license rights to two distinct classes of neutralizing monoclonal antibodies discovered at the University of Rochester in the laboratory of Dr. Eddie Schwarz, Burton Professor of Orthopaedics and Director of the Center for Musculoskeletal Research at the University of Rochester Medical Center. The Company is based in San Diego, California.

Encinitas, Ca, Us

Assisting in portfolio strategy and Advisory Board development for Sweetwater's life sciences portfolio companies. Advising Sweetwater principals on client communications to build on existing General Partner services offerings to institutional clients.

Member of the Board of DirectorsCompensation Committee 2012-2014

Foundation focused on translational medicine for the development of regenerative medical therapies of the central nervous system.

Sunnyvale, California, Us

Member of the Board of DirectorsCompensation Committee 2013-present

Celebration, Fl, Us

New York, New York, Us

Us

Us

Boston, Ma, Us

(previously Aurora Biosciences)

Dublin 2, Ie

Phd, Genetics And Developmental Biology

B.S., Microbiology And Botany (Double Major)

Education record